Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Galera Therapeutics, Inc.

GRTX · — · CIK 0001563577 · Healthcare

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

8 Form 4 transaction lines observed in the same window
0 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchase2024-12-30 · CHANG NANCY T · $535.1K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
CHANG NANCY TDirector,TenPercentOwner
○○
FRIEDMAN MICHAEL R.Director
○○
Emerald Bioventures, LLC; Opler TimothyTenPercentOwner
○
Sorensen MelPresident and CEO
○
Alleva Lawrence MDirector
○
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-12-30 · CHANG NANCY T.

Recent Form 4 activity

0Purchases
1Sales
10Other Form 4 lines
8SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

The FINRA report lists no short interest for this ticker.

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2024-12-30CHANG NANCY TPurchase (P)Common Stock7,644,932USD 0.07USD 535,145SEC filing ↗
2024-04-19Schneid YairPurchase (P)Common Stock100,000USD 0.19USD 19,000SEC filing ↗
2024-04-18Schneid YairPurchase (P)Common Stock547,600USD 0.20USD 108,348SEC filing ↗
2024-04-17Schneid YairPurchase (P)Common Stock1,764,657USD 0.22USD 392,558SEC filing ↗
2024-02-08Schneid YairPurchase (P)Common Stock150,000USD 0.17USD 25,500SEC filing ↗
2024-02-07Schneid YairPurchase (P)Common Stock175,000USD 0.17USD 29,750SEC filing ↗
2024-02-06Schneid YairPurchase (P)Common Stock25,000USD 0.20USD 5,000SEC filing ↗
2024-02-05Schneid YairPurchase (P)Common Stock97,402USD 0.18USD 17,532SEC filing ↗
2024-01-30Schneid YairPurchase (P)Common Stock335,000USD 0.18USD 60,300SEC filing ↗
2024-01-29Schneid YairPurchase (P)Common Stock150,000USD 0.18USD 27,000SEC filing ↗
2023-03-16Bachleda MarkPurchase (P)Common Stock11,000USD 2.25USD 24,750SEC filing ↗
2023-03-13Degnan ChrisPurchase (P)Common Stock10,000USD 1.96USD 19,600SEC filing ↗
2023-03-10Sorensen MelPurchase (P)Common Stock100,000USD 1.68USD 168,000SEC filing ↗
2021-12-17West LindaPurchase (P)Common Stock20,000USD 2.74USD 54,800SEC filing ↗
2021-06-15West LindaPurchase (P)Common Stock10,000USD 9.13USD 91,300SEC filing ↗

Form 4 evidence

11 transaction lines in the latest 365-day window; 110 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-03Sorensen MelD (D)Common Stock975USD —USD —SEC filing ↗
2026-08-03FRIEDMAN MICHAEL R.D (D)Common Stock41,631USD —USD —SEC filing ↗
2026-08-03CHANG NANCY TD (D)Common Stock47,434USD —USD —SEC filing ↗
Show recent Form 4 evidence (10 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-03Sorensen MelD (D)Common Stock975USD —USD —SEC filing ↗
2026-08-03FRIEDMAN MICHAEL R.D (D)Common Stock41,631USD —USD —SEC filing ↗
2026-08-03CHANG NANCY TD (D)Common Stock47,434USD —USD —SEC filing ↗
2026-08-03Alleva Lawrence MD (D)Common Stock51USD —USD —SEC filing ↗
2026-05-15FRIEDMAN MICHAEL R.C (C)Common Stock2,989,399USD —USD —SEC filing ↗
2026-05-15CHANG NANCY TC (C)Common Stock661,309USD —USD —SEC filing ↗
2026-05-15Emerald Bioventures, LLC; Opler TimothyC (C)Common Stock20,813,818USD —USD —SEC filing ↗
2026-04-07FRIEDMAN MICHAEL R.C (C)Common Stock5,336,870USD —USD —SEC filing ↗
2026-04-07CHANG NANCY TC (C)Common Stock1,180,611USD —USD —SEC filing ↗
2025-11-20Sorensen MelSale (S)Common Stock70,000USD 0.02USD 1,400SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerGRTX
CIK0001563577
SectorHealthcare
Industry— Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
Exchange—

Data coverage

Local Form 4 history110 transaction lines from 2020-05-05 to 2026-08-03
37 P purchase lines · 39 S sale lines · 34 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.